NCT01429155View on ClinicalTrials.gov

Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B

CompletedOBSERVATIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

March 31, 2013

Conditions
Hepatitis C
Interventions
GENETIC

Interleukin 28B genotype

Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)

Trial Locations (1)

48202

Henry Ford Hospital, Detroit

All Listed Sponsors
lead

Henry Ford Health System

OTHER

NCT01429155 - Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B | Biotech Hunter | Biotech Hunter